iBASIS Partners with SIPPIO to Meet Fast-Growing Demand for Unified Cloud Communications
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, announced it will partner with SIPPIO, the largest, secure, Azure-based provider of voice-calling services for Microsoft Teams, globally. The relationship enables both companies to address the fast-growing global demand for unified communications and collaboration services with Cloud Numbering and International Voice Termination.
The seismic shift to all cloud-based communication platforms is exemplified by Microsoft Teams’ 145 million daily active users. As recently reported by Synergy Group Research, “Microsoft has become the second-largest Unified Communications-as-a-Service (UCaaS) provider in the world.” As usage increases, so does the demand for exponentially growing voice calling services.
iBASIS and SIPPIO are responding to this demand with iBASIS’ expansion of Cloud Numbering and International Voice Termination combined with SIPPIO’s fully automated, end-to-end cloud solution platform, delivering top-grade communications and carrier services and leveraging automation to eliminate the cost, complexity, and time of building direct routing as a ‘one-off.’ This ensures both reliability and redundancy on a global scale with the highest levels of security, compliance, and data privacy.
iBASIS provides SIPPIO with enhanced coverage in various hard-to-reach destinations across the globe. Recent examples of iBASIS’ strengths in addressing demand from key geographies include iBASIS’ partnership with China Telecom Europe, which enabled CTE to achieve instant traction by leveraging iBASIS Carrier Voice for Teamwork™ to provide European multinationals with full calling capabilities to their collaboration platforms.
“SIPPIO is an innovative cloud solution player forging new capabilities and commercialization opportunities for fully automated, cloud-based direct routing as a service,” says Edwin van Ierland, Chief Commercial Officer and Chief Operating Officer at iBASIS. “This relationship showcases how iBASIS’ Carrier Cloud Communications portfolio, global reach, scale, and independence are critical to the global requirements for cloud communications.”
“This is a pivotal moment in which the demand to shift voice calling to the same world as online meetings is a major market driver,” adds Dawn-Marie Elder, COO, SIPPIO. “Partnering with iBASIS extends SIPPIO’s global footprint, reinforcing our ability to provide operators with the highest quality, tier-1 voice capabilities and fastest time to market to bring these solutions to their enterprise customers.”
iBASIS Carrier Voice for Teamwork is part of iBASIS’ larger Carrier Cloud Communications portfolio that includes cloud numbering solutions, international numbers, global voice termination, and Communications Platform as a Service (CPaaS). iBASIS’ carrier-grade API marketplace includes a full CPaaS suite to meet the growing and urgent need for collaborative tools and applications – including solutions for iBASIS Carrier Voice for Teamwork™, two-factor authentication, live support, and contact center services.
SIPPIO empowers channel partners and carriers with capabilities to capitalize on the demand for voice-enabled collaboration platforms like Microsoft Teams. By minimizing resource consumption from end to end, SIPPIO expands the universe of potential customers for partners, making it economically viable to pursue smaller companies as well as Fortune 500 enterprises.
About iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player. iBASIS today serves 1,000+ customers across 18 offices worldwide. For more information, please visit iBASIS.com.
About SIPPIO
Headquartered in Annapolis, MD, SIPPIO is the largest platform provider to enable voice in Microsoft Teams. As a Co-Sell Preferred partner, SIPPIO provides partners and carriers with a fully automated, Azure native, end-to-end solution. Available globally with toll-free and emergency services, SIPPIO does not require any code, build, or maintenance. SIPPIO activates full calling capabilities in minutes and scales with business needs to enhance communications and collaboration to unify the modern workplace experience. Visit www.sippio.io for additional information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005768/en/
Contact information
iBASIS Media
Melissa Coffman
26FIVE
mc@26Five.com
202-251-1793
SIPPIO Media
Mostafa Razzak
JMRConnect
m.razzak@jmrconnect.net
202.904.2048
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new